The spectrum of non-fatal immune-related adverse events following COVID-19 vaccination: The population-based cohort study in Seoul, South Korea
Suh, J. H.; Kim, H. J.; Kim, M.-H.; Choi, M. G.; Chun, E. M.
Show abstract
Much of the current literature on the adverse effects occurring after the coronavirus disease-2019 (COVID-19) vaccination focused on serious adverse events (AEs). Consequently, the non-serious AEs have yet to be comprehensively elucidated. This study aims to investigate the incidence rate and risk of non-serious AEs including gynecological, hematological, dermatological, ophthalmological, otologic, and dental problems following the COVID-19 vaccination. We conducted a population-based cohort study was conducted with the National Health Insurance Service (NHIS) database in Seoul, South Korea. The cumulative incidence rate (cIR) per 10,000 population, Odds ratio, and Hazard ratio (HR) with a 95% Confidence Interval (CI) were measured to assess the non-serious AEs, as reported by the Vaccine Adverse Event Reporting Center, after COVID-19 vaccination. The cIR of non-serious AEs for three months was significantly higher in vaccinated subjects than in non-vaccinated subjects, except for endometriosis. The vaccination significantly increased the risks of all the non-serious AEs except for visual impairment. The risk of inner ear disease showed the highest HRs (HR [95% CI] = 2.37 [2.15-2.60]) among the non-serious AEs following COVID-19 vaccination. Among the vaccinated subjects, heterologous vaccination was associated with the increased risk of most of the non-serious AEs. The three-month risks of incidental non-serious AEs are substantially higher in the COVID-19 vaccinated subjects than in non-vaccinated controls. Our findings suggested that vaccinated subjects with predisposition are potentially vulnerable to the occurrence of broad-spectrum AEs although the COVID-19 vaccines may not be serious.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Persistent health issues, adverse events of significant concern, and effectiveness of COVID-19 vaccination- findings from a real-world cohort study of healthcare workers in north India 95%
- Systemic adverse effects induced by the BNT162b2 vaccine are associated with higher antibody titers from 3 to 6 months after vaccination 95%
- Safety and efficacy of two immunization schedules with an inactivated SARS-CoV-2 vaccine in adults. A randomized non-inferiority clinical trial 94%
Similar papers in this journal
- Predictors for Reactogenicity and Humoral Immunity to SARS-CoV-2 Following Infection and mRNA Vaccination: A Regularized Mixed-Effects Modelling Approach 92%
- Cellular and humoral immune response to a third dose of BNT162b2 COVID-19 vaccine – a prospective observational study 92%
- Robust antibody levels in both diabetic and non-diabetic individuals after BNT162b2 mRNA COVID-19 vaccination 92%
Similar papers in this journal
- Effectiveness of inactive COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China 94%
- Comparison of Antibody Response Durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 Vaccines in Healthcare Workers 92%
- Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study 92%
Similar papers in this journal
- Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study 94%
- Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine 93%
- Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents 92%
Similar papers in this journal
- An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine 94%
- Antibody Response after Second-dose of ChAdOx1-nCOV (Covishield™ ® ) and BBV-152 (Covaxin™ ® ) among Health Care Workers in India: Final Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study 94%
- A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.